Urinary Markers/Cytology. What and When Should a Urologist Use

Jeffrey M. Tomasini, Badrinath R. Konety

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


As of 2012, bladder cancer is the fourth most common cancer afflicting men and ninth most common cancer in women. Nearly 80% of all bladder cancer diagnoses are non-muscle invasive at presentation, most of whom will develop recurrent disease within 5 years of initial diagnosis. Urinary tumor markers provide a noninvasive method for both screening and surveillance of bladder cancer. This article reviews the current Food and Drug Administration-approved urinary biomarkers for detection of non-muscle invasive bladder cancer.

Original languageEnglish (US)
Pages (from-to)165-173
Number of pages9
JournalUrologic Clinics of North America
Issue number2
StatePublished - May 2013


  • BTA
  • Cytology
  • ImmunoCyt
  • NMP22
  • Non-muscle invasive bladder cancer
  • UroVysion FISH


Dive into the research topics of 'Urinary Markers/Cytology. What and When Should a Urologist Use'. Together they form a unique fingerprint.

Cite this